CYP11B2 and adenoma: A recent study by De Sousa et al. using CYP11B2 immunohistochemistry as a tool to guide the identification of mutations in conjunction with NGS demonstrated that as high as 93.75% of adenomas had an aldosterone-driving mutation [14].